fbpx
  • About us
  • Advertise
  • Contact
  • Nominate
  • Client’s Voice
  • Login
  • Register
📖 Magazine
The Global Economics
  • Home
  • Banking
  • Non Banking
  • Markets
  • Infrastructure
  • Lifestyle
  • FeatureNew
  • Awards
No Result
View All Result
  • Home
  • Banking
  • Non Banking
  • Markets
  • Infrastructure
  • Lifestyle
  • FeatureNew
  • Awards
No Result
View All Result
The Global Economics
No Result
View All Result
Home Infrastructure Healthcare

Heart attacks to end by editing human DNA

New therapy will sharply reduce levels of cholesterol that cause heart attacks

Sunil Bolar by Sunil Bolar
May 9, 2022
in Healthcare, The Global Economics, Top Stories
Reading Time: 3 mins read
0
Heart attacks to end by editing human DNA

Heart attacks to end by editing human DNA

70
SHARES
391
VIEWS
FacebookTwitterRedditWhatsAppLinkedInShare Link

After decades of research and many drug therapy breakthroughs aimed at preventing heart attacks, they continue to be the leading cause of fatality in the world. Medicines available on the market aim to reduce the prevalence of heart attacks by reducing cholesterol levels that clog arteries and put people at risk. However, not everybody has access to these drugs, and among those that do, compliance with a treatment plan that lasts for a lifetime often proves untenable. 

In a new breakthrough, Verve Therapeutics Inc. has proposed a radical new therapy – altering the human genome itself – to stop the accumulation of bad cholesterol that causes heart attacks.

Sekar Kathiresan, CEO of Verve has said that the company is on the verge of making the treatment a one-time option for eligible patients. Initially, Verve plans to target those people who have already suffered a heart attack due to extremely high levels of cholesterol. Typically, this is a hereditary condition known as familial hypercholesterolemia, and affects more than 31 million people globally. The company has said that if the treatment works to lower the levels of LDL (low-density lipoprotein), commonly known as bad cholesterol, it would widen the treatment pool with an ultimate aim of providing the treatment to younger people as a preventive measure.

Verve Therapeutics Inc. is backed by Google Ventures (GV) and leading biotech investors, Arch Venture Partners and F-Prime Capital. The company reached a market cap of USD 2.89 billion last year.

New therapy aims to reduce heart problems

The medicine that Verve is developing is focused on two genes. The first treatment is targeted at PCSK9, while the second medicine is targeted at ANGPTL3. While some patients might only need one medicine, others will need both for an effective treatment. The company will use the Crispr DNA editing toll that alters a single letter of a person’s genome. A lipid nanoparticle encases the editing system and protects it while it travels to the liver, where it turns off the desired gene.

In trials with monkeys, the treatment showed encouraging signs, lowering bad cholesterol levels by up to 59 percent and sustaining the effect after six months of the treatment. The company is scheduled to begin human trials in just a few months, after which it will seek approval from regulators for commercial use. 

Elizabeth McNally, Director of the Centre for Genetic Medicine at Northwestern University Feinburg School of medicine, says that the company will face many hurdles in its attempt to provide mainstream therapy using DNA editing. Many people who resisted taking the Covid-19 vaccine could be wary of altering their DNA, she further added.

Another hurdle that Verve is likely to face is the high cost of the treatment. Statins, which were medicines first invented 35 years ago to lower cholesterol levels, are now available for as little as USD9 per month. A later alternative, self-injectable medication known as PCSK9 inhibitors, is only available to a few patients due to its high cost which runs into thousands of dollars a year. Till now, analysts have predicted that the cost of therapy from Verve will be approximately USD 50,000 to USD 200,000 per patient. Kathiresan has stated that the estimated amount is a reasonable forecast for the cost of therapy.

According to the CEO, many people do not take advantage of existing treatments, while an infusion given to a young person could alter their risk of heart attack for the rest of their lives. He also added that this new treatment could be the answer to heart attacks, if it works effectively.

 

Via: short URL
Tags: cholesterolDNAgene therapyheart attack
Sunil Bolar

Sunil Bolar

Sunil is a creative person who combines his love for writing with tech and business.

Related Posts

Unlocking Possibilities with ChatGPT: What AI-Assisted Conversation Could Mean for You?
The Global Economics

Unlocking Possibilities with ChatGPT: What AI-Assisted Conversation Could Mean for You?

by Riya Thomas
February 7, 2023
AMC Theatre
The Global Economics

Want a Seat In The Middle of The Theatre? Pay More: AMC Movies

by Marifur Rahman
February 7, 2023
Contact- Egypt's Leading Financial Services Company Harnesses the Power of Artificial Intelligence
Exclusive Coverage

Contact- Egypt’s Leading Financial Services Company Harnesses the Power of Artificial Intelligence

by The Global Economics
February 7, 2023
Japanese map with flag
Banking

Japan Govt Approaches Amamiya Regarding Becoming BOJ Governor

by Anuj Singh
February 7, 2023
Electric data centre
Technology

Oracle To Invest $1.5 Billion Data Centre In Riyadh, Saudi Arabia

by Anuj Singh
February 6, 2023
Facebook Twitter Instagram Youtube LinkedIn Soundcloud
The Global Economics

The Global Economics Limited is a UK based financial publication and a quarterly business magazine giving thoughtful insights into the financial sectors on various industries across the world. Our highlight is the prestigious country specific Annual Global Economics awards program where the best performers in various financial sectors are identified worldwide and honoured.

DMCA.com Protection Status

  • Privacy
  • Legal
  • Terms of Use
  • Client’s Voice
  • Server Status

norton verified - the global economics

Latest Posts

Unlocking Possibilities with ChatGPT: What AI-Assisted Conversation Could Mean for You?

Unlocking Possibilities with ChatGPT: What AI-Assisted Conversation Could Mean for You?

February 7, 2023
AMC Theatre

Want a Seat In The Middle of The Theatre? Pay More: AMC Movies

February 7, 2023
Contact- Egypt's Leading Financial Services Company Harnesses the Power of Artificial Intelligence

Contact- Egypt’s Leading Financial Services Company Harnesses the Power of Artificial Intelligence

February 7, 2023
Download The Global Economics PWA to your mobile or Desktop
PWA App Download
Download The Global Economics Android App to your mobile or Desktop
Android App
Download The Global Economics IOS App to your mobile or Desktop
IOS App

All Rights Reserved © 2020 | 🇬🇧 The Global Economics, Business Finance Publication - www.theglobaleconomics.uk 🌏

No Result
View All Result
  • About us
  • Awards
  • Magazine
  • Client’s Voice
  • Exclusive Coverage
  • Nominate
  • Login
  • Sign Up

All Rights Reserved © 2020 | 🇬🇧 The Global Economics, Business Finance Publication - www.theglobaleconomics.uk 🌏

Welcome Back!

Sign In with Facebook
Sign In with Linked In
OR

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Sign Up with Facebook
Sign Up with Linked In
OR

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
-
00:00
00:00

Queue

Update Required Flash plugin
-
00:00
00:00
Go to mobile version